Who are PEG-Tα1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TIMOFÉROL®, CMP 001, Intravenous immune globulin G, Thymosin alpha1 & Pegylated Interferon-alpha2a, Ganoderma lucidum, Ixazomib plus low-dose lenalidomide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-t-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PEG-Tα1 — Competitive Intelligence Brief

PEG-Tα1 (PEG-Tα1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; pegylated peptide. Area: Immunology; Infectious Disease.

phase 3 Immunomodulator; pegylated peptide T-cell maturation pathway; thymosin alpha 1 receptor Immunology; Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PEG-Tα1 (PEG-Tα1) — Jiangsu Hansoh Pharmaceutical Co., Ltd.. PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PEG-Tα1 TARGET	PEG-Tα1	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	Immunomodulator; pegylated peptide	T-cell maturation pathway; thymosin alpha 1 receptor
TIMOFÉROL®	TIMOFÉROL®	Assistance Publique - Hôpitaux de Paris	marketed	Thymic extract / Immunomodulator
CMP 001	cmp-001	Pfizer Inc.	marketed	Immunomodulatory Agent	TLR9
Intravenous immune globulin G	Intravenous immune globulin G	Rutgers, The State University of New Jersey	marketed	Immunoglobulin replacement therapy / Immunomodulator	Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens)
Thymosin alpha1 & Pegylated Interferon-alpha2a	Thymosin alpha1 & Pegylated Interferon-alpha2a	Seoul National University Hospital	marketed	Immunomodulator combination	T-cell maturation pathway; interferon-alpha receptor (IFNAR)
Ganoderma lucidum	Ganoderma lucidum	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Herbal/botanical immunomodulator
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; pegylated peptide class)

Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG-Tα1 — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-t-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab